



ASX RELEASE

Appointment of Michael Spooner to Board

Brisbane, Australia, 10 February, 2004: The Directors of **Peplin Biotech Ltd (ASX:PEP)** are pleased to announce the appointment of Michael Spooner as a non-executive member of Peplin's Board of Directors, effective immediately.

Until recently Mr Spooner was the Managing Director and CEO of Ventracor Limited (ASX:VCR). During his tenure with Ventracor he oversaw the company's rapid transition into one of Australia's leading life science companies and the second highest performer on the S&P ASX:200 in 2003.

Mr Spooner has extensive international experience. A former management consultant and partner in two of the world's largest professional service firms, he has well proven credentials.

In welcoming Michael to the Board, Peplin's Chairperson Dr Cherrell Hirst commented "Michael's significant business expertise together with the experience he has gained as CEO of a rapidly growing, highly successful biomedical company will be invaluable for Peplin as we move into the next phase of our growth and development."

New board member Michael Spooner commented "I am absolutely delighted to be joining the Board at this exciting period of time for Peplin. I particularly look forward to working closely with a very professional team of Board members and management".

ABOUT PEPLIN BIOTECH

Peplin Biotech Ltd is a biotechnology company based in Brisbane, Australia, focused on discovering and developing prescription human therapeutic products for the treatment of cancer. Its strategy is to leverage its pipeline of novel proprietary products through collaborative development arrangements with international pharmaceutical companies. Peplin's lead product is a potential topical therapy for actinic keratosis and non-melanoma skin cancer. This product is the subject of a joint development and licence agreement with Allergan, Inc. of Irvine California.

Peplin's earlier stage pipeline is targeted at other forms of cancer using topical, intralesional and systemic routes of administration. Its new portfolio of EPUFA compounds opens additional potential opportunities in cancer and adds candidates for cardiovascular disease, pain, inflammation and diabetic complications.

Further information:

Michael Aldridge
Managing Director & CEO
Peplin Biotech Ltd
Tel: 07-3854-0980
michael.aldridge@peplin.com

Peplin Biotech Ltd ABN 55 090 819 275

Ground Floor, South Tower, Terrace Office Park, 527 Gregory Terrace, Bowen Hills, Queensland 4006, Australia.

Tel: 61-7-3854 0980

Fax: 61-7-3854 0989

www.peplin.com